Bolt Biotherapeutics, Inc.
BOLTNASDAQHealthcare● Active
$4.72
+$0.16(+3.51%)
Market Cap$9069796
P/E Ratio—
52W High$7.35
52W Low$3.91
Bolt Biotherapeutics, Inc. (BOLT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BOLT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.70M | $7.69M | $7.88M | $5.73M | $1.26M |
| Cost of Revenue | $1.49M | $0.00M | $61.54M | $73.12M | $75.66M |
| Gross Profit | $6.20M | $7.69M | ($53.67M) | ($67.39M) | ($74.39M) |
| Gross Margin %(computed) | 80.62% | 100.00% | -681.39% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $28.53M | $57.47M | $61.54M | $73.12M | $75.66M |
| G&A Expenses | $13.79M | $18.46M | $22.53M | $22.93M | $18.39M |
| Total Operating Expenses | $40.84M | $80.74M | $22.53M | $22.93M | $18.39M |
| Operating Income | ($34.63M) | ($73.05M) | ($76.20M) | ($90.32M) | ($92.79M) |
| Operating Margin %(computed) | -450.07% | -949.91% | -967.45% | — | — |
| Interest Income | $2.50M | $5.25M | $7.00M | $2.22M | $0.28M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($33.38M) | ($63.12M) | ($69.20M) | ($88.10M) | ($98.59M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($33.38M) | ($63.12M) | ($69.20M) | ($88.10M) | ($98.59M) |
| Net Margin %(computed) | -433.74% | -820.78% | -878.58% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-17.85 | $-1.65 | $-1.83 | $-2.30 | $-2.79 |
| Wtd Avg Shares | 1.87M | 38.18M | 37.81M | 37.36M | 37.40M |
| EBITDA | ($33.14M) | ($66.45M) | ($74.34M) | ($88.66M) | ($91.59M) |
| EBITDA Margin %(computed) | -430.70% | -864.17% | -943.91% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Bolt Biotherapeutics, Inc. data
About Bolt Biotherapeutics, Inc. (BOLT) Income Statement
Bolt Biotherapeutics, Inc. (BOLT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BOLT reported revenue of $0.01B, gross profit of $0.01B (gross margin 80.62%), and net income of ($0.03B) — a net profit margin of -433.74%.
Frequently asked questions
BOLT · 4 questionsBolt Biotherapeutics, Inc. (BOLT) reported revenue of $0.01B for 2025, up 0.1% year-over-year.
BOLT revenueBOLT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08